Q3 2025 Earnings Call Transcript October 28, 2025 Operator: Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals ...

Patients with obesity and asthma who used GLP-1 receptor agonists had significantly fewer exacerbations and prednisone use ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

But to ensure the closest shave possible, while also avoiding irritation and ingrown hairs — not to mention painful nicks — ...

Electra Therapeutics has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline treatment for secondary ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net ...

Q3 2025 Earnings Call October 28, 2025 8:00 AM EDTCompany ParticipantsAlexis SmithWilliam Meury - CEO, President ...

He might look confident and in control, but under the surface these habits reveal a softer, more submissive side.

Gen Z transformed digital life. Gen Alpha, born fully into it, will decide what the next era of influence and consumption ...